abstract |
TLR agonists such as streptavidin (SA) -4-1BBL and monophosphoryl lipid A (MPL) show surprising synergistic effects as adjuvants and induce immune responses against weak antigens. Thus, an adjuvant composition containing a Toll-like receptor (TLR) agonist such as 4-1BBL and MPL, a subject is administered (a) an antigen, (b) a TLR agonist, and (c) 4-1BBL A method of inducing an immune response to an antigen in a subject, and administering to the subject (a) an antigen associated with a tumor or cancer, (b) a TLR agonist, and (c) 4-1BBL A method of treating a tumor or cancer in a subject is provided. [Selection figure] None |